Jared Gollob - 04 May 2022 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role: Chief Medical Officer
Signature: /s/ Bruce N. Jacobs, as Attorney-in-Fact
Issuer symbol: KYMR
Transactions as of: 04 May 2022
Net transactions value: +$33,740
Form type: 4
Filing time: 04 May 2022, 09:02:58 UTC
Previous filing: 03 Mar 2022
Next filing: 03 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KYMR	Common Stock	Options Exercise	$13,372	+10,208	+27%	$1.31^*	47,465	04 May 2022	Direct
transaction	KYMR	Common Stock	Options Exercise	$20,367	+9,792	+21%	$2.08^*	57,257	04 May 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KYMR	Stock Option (Right to Buy)	Options Exercise	$0	-10,208	-26%	$0.000000	29,799	04 May 2022	Common Stock	10,208	$1.31	Direct	F1
transaction	KYMR	Stock Option (Right to Buy)	Options Exercise	$0	-9,792	-8.2%	$0.000000	109,020	04 May 2022	Common Stock	9,792	$2.08	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Twenty-five percent (25%) of the shares underlying this stock option vested on September 12, 2019 and the remaining shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.
F2	The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.